Humana: The Star Rating Hit Is Real, But The Stock Has Already Had Its Reward

Rating: Hold

A competitor note claims Humana (HUM) is 25% overvalued after the company lowered its full-year GAAP EPS guidance. That headline sounds urgent. The reality is less clear-cut — and the stock's 109% gain over the past four months complicates the picture far more than a single guidance cut.

Humana is not 25% overvalued. But it is not a bargain either. After a rally that took the stock from $163 to $385 in 120 days, the risk/reward has normalized. The question now isn't whether the Star Rating problem is structural — it isn't — but whether there's enough near-term catalyst left to justify adding at these levels.

What Changed On The Earnings Call

Humana reported Q2 2026 revenue of $40.9 billion, beating the $40.6 billion consensus. Adjusted EPS came in at $7.61 versus a $7.22 estimate. The medical benefit ratio (the share of premiums spent on member care costs) hit 91.2%, in line with guidance. On those metrics, the quarter was solid.

The disappointment was in the full-year outlook. Management cut FY 2026 GAAP EPS guidance from "at least $8.36" to "at least $6.52" — a roughly 22% reduction. Adjusted EPS guidance was maintained at "at least $9.00," and consolidated revenue guidance held at "$160 billion." The medical benefit ratio target for the year stayed at 92.75%, plus or minus 25 basis points.

The stock fell more than 4% in premarket trading on July 29 despite the beat. Cantor Fitzgerald analysts called the unchanged adjusted profit outlook a disappointment relative to recent guidance raises by other private Medicare Advantage insurers.

The Star Rating Overhang — And Why It's Largely A One-Year Problem

The GAAP EPS cut traces directly to Humana's declining Medicare Advantage Star Ratings. CMS (the Centers for Medicare & Medicaid Services) awards quality bonus payments to MA plans rated at 4 stars or higher on a five-star scale. These bonuses increase per-member reimbursement from the government and can add billions to an insurer's bottom line.

For 2026, only 20% of Humana's MA members sit in plans rated 4 stars or above, down from 25% in 2025 and dramatically below the 94% recorded in 2024. The drop was driven largely by one of Humana's largest contracts falling from 4.5 to 3.5 stars. For context, 78% of UnitedHealthcare members and 55% of Elevance members are served by top-rated plans. Humana is expected to receive only $1.5 billion of the $13.4 billion total federal MA quality bonus spending in 2026 — just 11% of the pie despite holding 20% of enrollment.

Humana has disclosed it expects to lose "billions of dollars in revenue" from the Star Rating decline. That is the primary driver of the GAAP EPS guidance cut.

But this is not a permanent structural problem. Several factors point to recovery:

• For 2026, 14% of Humana's members are now in 4.5+ star plans, up sharply from 3% in 2025. The mix is shifting even as the headline percentage of 4+ star members dropped.
• Management expects the percentage of members in 4+ star plans to be "meaningfully higher" in 2027.
• Humana plans to exit approximately 600,000 members from lower-return MA plans in 2027, a move designed to improve both profitability and Star Rating concentration.
• The company's longer-term target is a 4-star average rating and a sustainable 3% pretax margin in individual MA plans by 2028.
• Excluding the Star Rating impact, Humana expects to double its pre-tax margin in individual MA plans for 2026.

The Star Rating hit is painful for 2026 GAAP earnings. It is not evidence that Humana's Medicare Advantage business is breaking.

Operating Metrics Still Support Growth

Setting aside the GAAP versus adjusted accounting question, the underlying business is expanding. Individual Medicare Advantage membership grew roughly 23% in Q2, and full-year growth is still guided at approximately 25% over 2025 levels. Humana reaffirmed that pace even as it prepares to shed lower-return plans next year.

The CenterWell senior primary care unit added 130,900 patients year-to-date, representing 27% growth. The company also won a statewide Medicaid managed care contract in Illinois, expected to go live in January 2027 — its only new state entry alongside five incumbents. These are incremental revenue lines that reduce Humana's dependency on Medicare Advantage alone.

Revenue growth of 18.3% year-over-year is solid for a mature insurer. The gross margin of 88.3% reflects the pass-through nature of insurance premiums. The real question is operating leverage — and at 1.8% operating margin and 2.4% EBITDA margin, Humana has a wide runway if it can hold costs below premium growth.

The risk on the cost side is pharmacy spending. CFO Celeste Mellet noted pharmacy costs remain "very elevated" due to drug prices and new medicines, and will be slightly higher in 2027 compared to 2026. This is an industry-wide trend, not a Humana-specific failure, but it caps how fast margins can expand.

Free cash flow of $1.95 billion over the trailing twelve months is down 20% year-over-year. That decline warrants watching, though the balance sheet remains stout: $6.9 billion in cash against $37.9 billion in total debt, with a net cash position of roughly $9.3 billion (accounting for debt classification differences). The company also completed a $276 million share repurchase recently.

Valuation: Cheap On Paper, But The Stock Already Moved

Here is where the "25% overvalued" claim starts to fall apart.

Humana's forward P/E of 12.9x is below UnitedHealth Group at 26.2x, Elevance Health at 17.2x, and even HCA Healthcare at 13.1x. On an EV/EBITDA basis, Humana trades at 10.6x versus 15.9x for UNH, 9.8x for ELV, and 8.8x for HCA. The price-to-sales multiple of 0.32x reflects the insurance business model where revenue is largely premium pass-through.

Against that peer backdrop, 12.9x forward earnings is not expensive. In fact, it is discounted relative to where the stock traded before the Star Rating problems surfaced.

But valuation is not the full story. This stock is up 50% year-to-date and up roughly 109% over 120 days. The move from $163 to $385 already priced in the expectation that Star Ratings would recover, that the 3% margin target by 2028 is achievable, and that membership growth would hold. The forward P/E looks cheap only because forward GAAP EPS estimates are depressed by the one-time Star Rating hit.

If you use the company's own adjusted EPS guidance of at least $9.00, the current price of $385 implies a multiple of roughly 43x on adjusted earnings. That is not a cheap multiple. The adjusted number strips out the Star Rating impact, which is the very thing that makes the forward GAAP P/E look so compressed.

Both multiples tell part of the truth. The GAAP multiple is suppressed by a temporary accounting hit. The adjusted multiple is real but assumes recovery that hasn't happened yet. The net result: fair value, not a bargain.

What Would Change The Rating

To upgrade to Buy: I would need to see either (1) the stock pull back toward the $280-$300 range, where the forward GAAP multiple would drop below 10x and give real margin of safety, or (2) 2027 Star Rating data confirming management's "meaningfully higher" guidance and a corresponding upward revision to the adjusted EPS outlook. The next earnings report will provide the earliest read on both.

To downgrade: A miss on the $9.00 adjusted EPS floor, a widening benefit ratio beyond the 92.75% +/- 25bps guidance range, or evidence that pharmacy cost escalation is eating into margins faster than premium pricing can offset would shift the risk/reward to the downside. The Illinois Medicaid launch timing and execution would also be a signal — a delayed go-live or underperforming member acquisition would suggest operational drag beyond the MA business.

Bottom Line

The competitor's "25% overvalued" claim overstates the downside. Humana's forward valuation is not rich, and the Star Rating problem is a one-year GAAP hit, not a structural failure. The company is growing membership, expanding into new Medicaid markets, and targeting meaningful margin recovery by 2028.

But the 109% rally over four months has already captured the turnaround narrative. At $385, the risk/reward is even. This is a Hold, not a buy. Wait for the stock to find a better entry point, or for 2027 Star Rating data to confirm that the worst is truly behind Humana before adding exposure.

The next earnings print, the 2027 Star Rating release, and the benefit ratio trajectory through Q3 will tell us which side of even the stock is on.